Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


July 10, 2006 10 July, 2006

Charles Allard Appointed to Board of Directors


Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Mr. Charles Allard, LLB of Edmonton, Alberta, has been appointed to the Board of Directors to assist Pheromone in its diabetes product development. Mr. Allard brings with him a history of successful business ventures in many fields including broadcasting, banking and real estate development.

Mr. Allard is presently a Director of Canadian Western Bank, Cathton Holding Ltd. and Allarco Entertainment Inc., and is President of Rosedale Meadow Developments Inc. He previously held board positions with WIC Premium Television Ltd., Canadian Satellite Communications Corp., ExpressVu Inc., Western International Communications Inc. The Family Channel, Teletoon, Northwest Trust Company and Allarco Developments. He has also recently been appointed a Director of the Alberta Diabetes Institute Advisory Board. He is active in several charitable organizations and serves as a Director of Young Life of Canada.

Mr. Allard completed his law degree at the University of British Columbia after graduating from Simon Fraser University's Bachelor of Science program. He was admitted to the Alberta Bar in 1973 and has practiced law continuously since then.

"We are delighted to have Mr. Allard join with us in moving this company towards a breakthrough in diabetes treatment," said Pheromone's Chairman Dr. William Cochrane. "He has shown his commitment to improving the lives of people with diabetes through his investments and charitable support of diabetes treatment and research."

About the Research Project Pheromone has recently completed a $3.2 million private placement to fund its research into an innovative treatment for Type 1 (insulin dependent) diabetes. Using rigorous and widely accepted scientific experimentation methods, the Company intends to develop a procedure for transplanting into humans a device containing pig islet cells and pig Sertoli cells. The islet cells produce insulin almost identical to that found in humans and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The goal of the project is to ultimately receive approval for the procedure from the United States Food and Drug Administration, and from other national regulatory bodies throughout the developed world. The research is based on several proof- of-concept experiments completed by Dr. David White, Pheromone's principal researcher, and others.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.



ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact:

Mr. Phil Morehouse Pheromone Sciences Corp.

TEL: (250) 868-8177 FAX: (250) 868-8493